Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pacific Biosciences of California, Inc. - Common Stock (NQ: PACB )

1.911 -0.039 (-2.01%)
Streaming Delayed Price Updated: 1:31 PM EST, Dec 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pacific Biosciences of California, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Inari Medical (NASDAQ:NARI) stock... 
Via Benzinga
Biotech Playbook 2021 Part 2: Rotation Rally Brings Relief after FED Pivot
The new aggressive Fed taper combined with a rise in interest rates for 2022 adds a new element of risk to portfolio management. Monetary policy is a headwind for 2022. 
Via Talk Markets
Looking for Growth in Small and Mid Cap Life Science Stocks
2021 is an unusual year for biotech with a “blow-off” February high in speculative small caps. 
Via Talk Markets
Earlier Screening and Aging Population Driving Surging Growth in Colorectal Diagnostics Demand
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – November 11, 2021 – New recommendations for colorectal cancer (CRC) screening by both the US Preventative Services Task Force... 
Via FinancialNewsMedia
Earnings Scheduled For November 2, 2021
Companies Reporting Before The Bell • Thomson Reuters (NYSE:TRI) is expected to report quarterly earnings at $0.48 per share on revenue of $1.86 billion. •... 
Via Benzinga
Pacific Biosciences Q3 Revenues Jump 83%, Says Sequel II/IIe Installations At All-Time High
Pacific Biosciences of California Inc (NASDAQ: PACB) reported Q3 sales of $34.9 million, beating the consensus of $33.23 million and up 83% Y/Y. The company... 
Via Benzinga
Pacific Biosciences of California (PACB) Q3 2021 Earnings Call Transcript
PACB earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus SAB Spikes On Analyst Action SAB Biotherapeutics, Inc. (NASDAQ: SABS) shares... 
Via Benzinga
Exposures COVID-19
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
3 Genomics Stocks That Could Soar 60% or Better, According to Wall Street
The genomic revolution is upon us and these stocks could be great vehicles for investors who want to take advantage of it. 
Via The Motley Fool
Class Of 2010: A Decade After Their IPOs, Where Are These Companies Now?
The year 2010 was a bumper year for IPOs, as more than twice as many new issues were floated as compared to the previous year. The IPO boom of the year was spearheaded by special purpose acquisition... 
Via Talk Markets
Topics Initial Public Offering
Exposures Securities Market
Class Of 2010: A Decade After Their IPOs, Where Are These Companies Now?
Initial public offerings provide companies with the wherewithal to pursue growth opportunities without having to bear the burden of repayment. What Is an IPO: An IPO is a... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
5 Largest US M&A Deals In Q2: Railways, Health Care, REITS And More
The second quarter started strong with four of the five largest deals announced in the month of April. 
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For September 27, 2021
Upgrades According to Roth Capital, the prior rating for Seelos Therapeutics Inc (NASDAQ: 
Via Benzinga
5 Largest US M&A Deals In Q2: Railways, Health Care, REITS And More
Global merger and acquisition activity topped $1 trillion in the second quarter of 2021, with the U.S alone topping $500 billion. This was the third quarter in a row that this... 
Via Benzinga
Week In Review: China Life Science Posts $1.3 Billion In Deals
Pacific Biosciences, a San Francisco Bay area company offering long-read sequencing platforms, will acquire Omniome for up to $800 million. Zai Lab and Schrödinger formed a collaboration to develop a... 
Via Talk Markets
Billionaire Masayoshi Son's SoftBank Claims $5B Stake In Roche: Bloomberg
SoftBank Group Corp (OTC: SFTBF) has quietly acquired a $5 billion stake in Roche Holdings AG (OTC: RHHBF), making it one of the largest investors of the Roche,... 
Via Benzinga
Pacific Biosciences of California (PACB) Q2 2021 Earnings Call Transcript
PACB earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Pacific Biosciences Q2 Earnings Beat Expectations, Higher Operating Costs Widens Quarterly Loss
Pacific Biosciences of California Inc (NASDAQ: PACB), after the close of the market on Tuesday, reported Q2 sales of $30.6 million, beating the consensus of $29.9... 
Via Benzinga
Topics Earnings
Exposures Financial
$5,000 Invested in These 3 Healthcare Stocks Could Make You Rich Over the Next 10 Years
These companies could upend the industry in the years ahead. 
Via The Motley Fool
Earnings Scheduled For August 3, 2021
Companies Reporting Before The Bell • Myriad Genetics (NASDAQ:MYGN) is likely to report earnings for its fourth quarter. • Stellantis (NYSE:STLA) is expected to... 
Via Benzinga
Pacific Biosciences To Buy DNA Sequencing Firm For Up To $800M, Announces $300M Capital Raise For Deal Funding
Pacific Biosciences of California Inc (NASDAQ: PACB) has agreed to acquire Omniome, a San Diego-based company developing a short-read sequencing platform. Under... 
Via Benzinga
This Biotech Just Made History. Will Its Stock Follow?
Twenty years after the human genome was sequenced, a new wave of discovery has begun. 
Via The Motley Fool
2 Winners for a Drug Development Future That Looks Nothing Like the Past
A new breed of disruptors is delivering breakthroughs in genomics. 
Via The Motley Fool
2 Top Biotech Picks to Buy and Hold for the Next 10 Years
Incredible scientific advances could reward investors -- if they have the patience. 
Via The Motley Fool
Cathie Wood's Ark Loads Up Further On Tesla And Cuts Apple Stake
Cathie Wood-led Ark Investment Management on Tuesday snapped up $27.2 million worth of shares in Tesla Inc (NASDAQ: TSLA) after a two-week gap during which shares of the... 
Via Benzinga
The Daily Biotech Pulse: Spero Secures NIAID Funding, GlaxoSmithKline Releases COVID-19 Data, BioNTech Gets New CFO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 17) Alexion Pharmaceuticals, Inc... 
Via Benzinga
Exposures COVID-19
'SPACs Attack' Recap: Looking Back At 8 SPAC Deals Plus Latest SPAC Headlines And Earnings
Last week featured eight announced SPAC deals. The week also had earnings from several well-known former SPACs. Here is a look back at the week that was SPACs for deals and... 
Via Benzinga
Cathie Wood Cuts Apple Stake Almost Entirely — And Buys More Coinbase
Cathie Wood-led Ark Investment Management on Monday shed nearly all of its stake in Apple Inc (NASDAQ: 
Via Benzinga
Cathie Wood Buys $26M Disney Shares And Sells $13M In Netflix: What You Need To Know
Cathie Wood-led Ark Investment Management on Friday bought 150,556 shares, worth about $26.15 million, in Walt Disney Co (NYSE: DIS), marking its debut in the media and... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.